Baricitinib was generally well-tolerated. Acne was the most common adverse event (17.6%), followed by dyslipidemia (7.8%). Asthenia, elevated liver enzymes, and weight gain each occurred in fewer than ...
Byrdie on MSN
You're not the only one dealing with hair thinning at the temples—experts explain why it's so common
Hair thinning at the temples is often due to genetics, specifically a condition known as androgenetic alopecia. Health ...
Despite being unable to declare statistical success, the company claimed its therapy showed enough promise to support moving ...
Nektar Therapeutics is planning to bring its interleukin-2-targeting drug candidate into a phase 3 trial for severe alopecia ...
Back in October, the 2025 Fall Clinical Dermatology Conference showcased some of the most exciting advances in skin disease treatment this year. From pill-based TYK2 inhibitors and durable IL-23 ...
Clascoterone 5%, a topical anti-androgen drug indicated for male pattern hair loss, demonstrated significant hair regrowth ...
Nektar Therapeutics reported Phase 2b alopecia areata data showing hair regrowth trends, narrowly missing significance before ...
Olumiant and other drugs like it had already been approved to treat autoimmune conditions like rheumatoid arthritis, but used off-label for alopecia.
Nektar Therapeutics stock is trading lower Monday afternoon as the market continues to assess mixed topline results from the ...
Patients with alopecia areata are at a greater risk for psychiatric disorders than control patients, including depression and anxiety, among others.
Here are the top 5 most-viewed alopecia content in 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback